CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 306-309

  Fukuoka, M ^a   Masuda, N ^a   Negoro, S ^a   Matsui, K ^a   Yana, T ^a   Kudoh, S ^a   Kusunoki, Y ^a   Takada, M ^a   Kawahara, M ^b   Ogawara, M ^b   Kodama, N ^b   Kubota, K ^b   Furuse, K ^b  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

CODE chemotherapy; Dose intensity; Extensive stage small cell lung cancer; Recombinant human granulocyte colony stimulating factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 8044245919     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.50     Document Type: Article

References (21)

1. Aisner J (1996) Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defect. J Clin Oncol 14: 658-665
2. Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H, Ikegami H and Smyth J (1983) Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67: 37-43
3. Alba E, Breton JJ, Alonso L, Paredes G, Belon J and Ballesteros P (1992) Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs [see comments]. Ann Oncol 3: 31-35
4. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG and Dexter TM (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56: 809-813
5. Cox D (1972) Regression models and life tables (with discussion). J R Stat Soc B, 34: 187-220
6. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M and Glaspy J (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Eng J Med 325: 164-170
7. Frei E and Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585-594
8. Fukuoka M, Masuda N, Takada M, Kodama N, Kawahara M and Furuse K (1994) Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Semin Oncol 21: 43-47
9. Kaplan E and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
10. Masuda N, Fukuoka M and Furuse K (1992) CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology I: 19-24
11. Miles DW, Earl HM, Souhami RL, Harper PG, Rudd R, Ash CM, James L, Trask CW, Tobias JS and Spiro SG (1991) Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 9: 280-285
12. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL and Harper PG (1994) Received dose-intensity: a randomised trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 12: 77-82
13. Murray N, Osoba D, Shah A, Page R, Karsai H and Little C (1991a) Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen. J Natl Cancer Inst 83: 190-194
14. Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R and Voss N (1991b) Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9: 1632-1638
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, Mepherson K, Peto J and Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39
16. SAS Institute (1986) SUGI Supplemented Library User's Guide version 5 edition, SAS Institute: Cary, NC
17. Sculier J-P, Klastersky J, Finet C, Ries F, Sergysels R and Mommen P (1990) Intensive multiple drug induction chemotherapy for small-cell lung cancer. A pilot study. Drug Invest 2: 99-104
18. Taylor CW, Crowley J, Williamson SK, Miller TP, Taylor SA, Giri TG, Stephens RL and Livingston RB (1990) Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J Clin Oncol 8: 1811-1817
19. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D and Ewen C (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A: 319-324
20. Wampler GL, Ahlgren JD and Schulof RS (1992) A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma. Cancer Invest 10: 97-102
21. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V and Thatcher N (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13: 652-659